삼진제약

005500KOSPISector: Pharma & Biotech

₩17,750▲ 1.43%Market cap ₩236.4BAs of Jul 21, 2026 close · updated once daily

Grade B59.7 ptsTop 34% of 2,523 stocks

Financial strength

59.8

Growth momentum

33.4

Price attractiveness

78.3

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

Financial strength

59.8

How much debt does it carry relative to equity?

Debt-to-equity ratio

62.0%

✗ Below median · Top 58.3% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

130.2%

✗ Below median · Top 62.8% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

8.7%

✓ Above median · Top 21.6% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

8.3%

✓ Above median · Top 18.1% in sector

Sector median -4.5%

Source filing: annual report (separate) — view original ↗

Growth momentum

33.4

How much did revenue grow in a year?

Revenue growth (YoY)

0.3%

✗ Below median · Top 66% in sector

Sector median 6.4%

Did core profits grow in a year?

Operating income change (YoY)

-15.3%

✗ Below median · Top 67.2% in sector

Sector median 3.6%

Source filing: annual report (separate) — view original ↗

Price attractiveness

78.3

Is the price expensive relative to earnings?

P/E (price-to-earnings)

9.8x

✓ Above median · Top 14.4% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

0.81x

✓ Above median · Top 29.1% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15